vs

Side-by-side financial comparison of MicroAlgo Inc. (MLGO) and Silence Therapeutics plc (SLN). Click either name above to swap in a different company.

MicroAlgo Inc. is the larger business by last-quarter revenue ($26.3M vs $15.7M, roughly 1.7× Silence Therapeutics plc).

MicroAlgo Inc. is a technology enterprise specializing in custom algorithm optimization solutions. It mainly serves clients across smart city management, industrial internet, and e-commerce sectors, helping enterprises improve operational efficiency, reduce operating costs, and optimize data processing performance for real business scenarios.

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

MLGO vs SLN — Head-to-Head

Bigger by revenue
MLGO
MLGO
1.7× larger
MLGO
$26.3M
$15.7M
SLN

Income Statement — Q2 FY2025 vs Q1 FY2024

Metric
MLGO
MLGO
SLN
SLN
Revenue
$26.3M
$15.7M
Net Profit
$-2.3M
Gross Margin
82.2%
Operating Margin
-35.6%
Net Margin
-14.7%
Revenue YoY
-35.5%
Net Profit YoY
EPS (diluted)
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MLGO
MLGO
SLN
SLN
Q2 25
$26.3M
Q4 24
$34.6M
Q2 24
$40.8M
Q1 24
$15.7M
Q2 23
$20.2M
Q1 23
$17.8M
Q2 22
$28.2M
Q1 22
$23.4M
Net Profit
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
$4.2M
Q2 24
Q1 24
$-2.3M
Q2 23
$-4.8M
Q1 23
$-1.3M
Q2 22
$-23.6K
Q1 22
$888.4K
Gross Margin
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
26.4%
Q2 24
Q1 24
82.2%
Q2 23
33.0%
Q1 23
27.8%
Q2 22
-0.1%
Q1 22
23.1%
Operating Margin
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
7.0%
Q2 24
Q1 24
-35.6%
Q2 23
-7.7%
Q1 23
-7.9%
Q2 22
-0.1%
Q1 22
5.0%
Net Margin
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
12.1%
Q2 24
Q1 24
-14.7%
Q2 23
-23.7%
Q1 23
-7.1%
Q2 22
-0.1%
Q1 22
3.8%
EPS (diluted)
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
$0.56
Q2 24
Q1 24
$-0.02
Q2 23
Q1 23
Q2 22
Q1 22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MLGO
MLGO
SLN
SLN
Cash + ST InvestmentsLiquidity on hand
$319.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$317.6M
$156.8M
Total Assets
$330.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MLGO
MLGO
SLN
SLN
Q2 25
$319.4M
Q4 24
$164.9M
Q2 24
$66.7M
Q1 24
Q2 23
$19.2M
Q1 23
$21.0M
Q2 22
$10.9K
Q1 22
$28.7K
Stockholders' Equity
MLGO
MLGO
SLN
SLN
Q2 25
$317.6M
Q4 24
$144.9M
Q2 24
$76.0M
Q1 24
$156.8M
Q2 23
$60.4M
Q1 23
$66.7M
Q2 22
$-3.0M
Q1 22
$-2.5M
Total Assets
MLGO
MLGO
SLN
SLN
Q2 25
$330.8M
Q4 24
$176.3M
Q2 24
$107.6M
Q1 24
Q2 23
$71.8M
Q1 23
$75.6M
Q2 22
$47.3M
Q1 22
$46.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MLGO
MLGO
SLN
SLN
Operating Cash FlowLast quarter
$-9.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
$4.8M
Q2 24
Q1 24
$-9.1M
Q2 23
$-3.8M
Q1 23
$-2.8M
Q2 22
$-747.8K
Q1 22
$456.6K
Free Cash Flow
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
$4.8M
Q2 24
Q1 24
Q2 23
Q1 23
$-2.8M
Q2 22
Q1 22
$270.9K
FCF Margin
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
13.8%
Q2 24
Q1 24
Q2 23
Q1 23
-15.8%
Q2 22
Q1 22
1.2%
Capex Intensity
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Q2 23
Q1 23
0.3%
Q2 22
Q1 22
0.8%
Cash Conversion
MLGO
MLGO
SLN
SLN
Q2 25
Q4 24
1.15×
Q2 24
Q1 24
Q2 23
Q1 23
Q2 22
Q1 22
0.51×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons